Article
Nanoscience & Nanotechnology
Jungho Kim, Se-Jin Park, Jisang Park, Hojeong Shin, Yong-Suk Jang, Jae-Sung Woo, Dal-Hee Min
Summary: Dengue virus causes infectious diseases, but there are no approved antiviral drugs. Developing antiviral agents targeting viral enzymes, such as helicase, is important. Helicase inhibition could serve as a direct-acting antiviral agent.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Virology
Dandan Liu, Tanya P. Ndongwe, Juan Ji, Andrew D. Huber, Eleftherios Michailidis, Charles M. Rice, Robert Ralston, Philip R. Tedbury, Stefan G. Sarafianos
Summary: Direct-acting antivirals (DAAs) provide interferon-free strategies for hepatitis C treatment, while host-targeting agents (HTAs) exhibit high resistance and distinct mechanisms of action. Our research shows that cyclosporin A (CsA), a HTA targeting cyclophilin A, can suppress HCV infection as quickly as DAAs, but has a different effect on intracellular virus replication.
Article
Public, Environmental & Occupational Health
Yadong Wang, Yangyang Hu, Xing Zhang, Yue Luo, Luyuan Ma, Jingjing Lu, Qianfei Liang, Chengjun Xu, Caiyan Zhao, Calvin Q. Pan
Summary: This study investigated the relationship between IP-10 and treatment response in patients with CHC treated with direct-acting antiviral agents. The results showed that IP-10 levels decreased gradually during the treatment and baseline IP-10 level and the decline at 12 weeks were independent predictors of SVR.
FRONTIERS IN PUBLIC HEALTH
(2022)
Review
Gastroenterology & Hepatology
Saleh A. Alqahtani, Massimo G. Colombo
Summary: The prevalence and burden of hepatitis C virus (HCV) in children are poorly understood. Vertical transmission and injection drug use are the main modes of infection. Early diagnosis and treatment are crucial in preventing HCV-induced severe liver disease. Direct-acting antiviral drugs have shown to be as safe and effective in young HCV patients as in adults.
LIVER INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Kuo-Tung Tang, Ching-Chun Lin, Yi-Hsing Chen, Tsai-Ling Liao, Der-Yuan Chen, Sheng-Shun Yang, Chia-Chang Chen
Summary: This study investigated the impact of direct-acting antiviral drugs (DAA) therapy on fibromyalgia (FM) symptoms in patients with chronic hepatitis C (CHC). The results showed that CHC patients were more likely to develop FM and implementation of DAA therapy might improve FM symptoms in these patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Garri Chilingaryan, Roza Izmailyan, Rafayela Grigoryan, Anastasiya Shavina, Erik Arabyan, Hamlet Khachatryan, Narek Abelyan, Mher Matevosyan, Vardan Harutyunyan, Gayane Manukyan, Benjamin Hietel, Anna Shtro, Daria Danilenko, Hovakim Zakaryan
Summary: We utilized advanced virtual screening to identify potential inhibitors of human DHODH, a validated target for broad-spectrum antivirals. Among 495118 screened compounds, 495 exhibited better binding scores than reference ligands. From the top 100 compounds, we selected 28 based on consensus docking scores and structural novelty. In vitro experiments demonstrated the antiviral activity of selected compounds on HSV-1 infection, with Comp 19 being the most potent inhibitor.
ANTIVIRAL RESEARCH
(2023)
Article
Virology
Heidar Sharafi, Bita Behnava, Alireza Azizi-saraji, Ali Namvar, Ali Anvar, Shima Salimi, Seyed Moayed Alavian
Summary: The study showed that DAA-based regimens are effective in treating CHC in patients with HBD, regardless of treatment modifiers like previous treatment experience, cirrhosis, HIV co-infection, and HCV genotype.
Review
Virology
Christopher Dietz, Benjamin Maasoumy
Summary: Hepatitis C virus infection poses a significant threat to human health, but the development of specific antiviral drugs has revolutionized the treatment and brought hope to patients.
Review
Chemistry, Medicinal
Chiara Tammaro, Michela Guida, Federico Appetecchia, Mariangela Biava, Sara Consalvi, Giovanna Poce
Summary: EV-B-related diseases are recognized as a serious health problem, but their clinical treatment is supportive and no selective antivirals are currently available. Recent advances in the discovery of new compounds with antiviral activity against EV-B and drug repurposing are discussed, highlighting current progress and future perspectives in EV-B drug discovery.
Article
Clinical Neurology
Mohamed A. Khalil, Hend Ibrahim Shousha, Saeed M. El-Nahaas, Mohamed Ibrahim Negm, Kariman Kamal, Nagwan Mohamed Madbouly
Summary: This study aimed to evaluate the incidence and potential risk factors of depression and psychological distress following DAAs therapy in CHC euthymic Egyptian patients with no previous or current diagnosis of any psychiatric disorders. The results showed that about one third of patients had moderate to severe depression following treatment.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Endocrinology & Metabolism
Chun-Han Cheng, Chia-Ying Chu, Huan-Lin Chen, I-Tsung Lin, Chia-Hsien Wu, Yuan-Kai Lee, Ming-Jong Bair
Summary: This study analyzed the factors associated with insulin resistance (IR) in chronic HCV-infected patients and evaluated the changes in glucose homeostasis after treatment with direct-acting antiviral agents (DAAs). The results showed that obesity, treatment experience, high serum ALT and triglyceride levels, as well as advanced hepatic fibrosis were independently associated with IR in these patients. After viral elimination with DAA therapy, there was a significant reduction in mean HOMA-IR in patients with baseline high IR, HCV genotype 1, and treatment experience.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Gastroenterology & Hepatology
Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan
Summary: This retrospective study in incarcerated HCV-infected patients in Singapore showed that unrestricted access to DAA significantly increased treatment access, completion rate, and reduced treatment default rate, highlighting the impact of this strategy in HCV micro-elimination efforts.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Lauren P. Jatt, Malini M. Gandhi, Rong Guo, Adam Sukhija-Cohen, Debika Bhattacharya, Chi-hong Tseng, Kara W. Chew
Summary: This study investigated the frequency of and potential barriers to DAA prescription in HIV/HCV coinfected patients during the early years of DAA availability in the United States. The results showed that, in addition to lack of HIV suppression, factors such as substance use, specific antiretroviral regimens, and kidney disease appeared to limit DAA prescription. Further research is needed to determine if these associations still exist today.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Virology
Shou-Wu Lee, Li-Shu Chen, Sheng-Shun Yang, Yi-Hsiang Huang, Teng-Yu Lee
Summary: In patients with BCLC stage B/C HCC, DAA therapy can achieve a high SVR rate, except for those with PD to prior HCC treatments. SVR is related to improvements in OS, therefore, DAA therapy should be encouraged for patients diagnosed without a short life expectancy.
Article
Gastroenterology & Hepatology
Maria M. Zanone, Claudia Marinucci, Alessia Ciancio, Dario Cocito, Federica Zardo, Emanuela Spagone, Bruno Ferrero, Cristina Cerruti, Lorena Charrier, Franco Cavallo, Giorgio M. Saracco, Massimo Porta
Summary: This longitudinal study assessed the prevalence and outcome of neuropathy in chronic HCV patients before and after DAA treatment. Results showed improvement in neuropathy after DAA therapy, supporting the need for larger intervention studies.
LIVER INTERNATIONAL
(2021)
